Top 10 Companies in Liquid Biopsy Detailed in New Report

Liquid biopsy encompasses various diagnostic methods that use liquid, non-tissue specimens to provide information that can aid in the diagnosis, treatment and monitoring of cancer. Currently, tissue biopsies, along with imaging techniques, are the standard methods used in the diagnosis of solid cancers, but despite their widespread use, they have many limitations that open the door for other diagnostic technologies in oncology clinical settings.

“Up to the present, several liquid biopsy diagnostic tests have been developed based on these technologies, and are currently commercialized for different types of cancers and applications,” said Bruce Carlson, Publisher of Kalorama Information.

Although in its early stages of development, the overall market is a dynamic and fast-developing one that is expected to evolve into a billion-dollar market by 2021. Geographically, the market participants are concentrated in the USA and Europe, with several competitors based also in Asia.  The liquid biopsy market is largely driven by technological innovation and high demand for non-invasive cancer diagnostic and monitoring tests, and focused thus far to a large extent on the development of tests for available clinically-actionable molecular targets and approved therapies. Another area of strong interest in this market is the development of tests for the diagnosis of cancer at earlier stages, when patients suffering from this disease have greater treatment options and chances of survival. These driving forces are expected to continue to exert a major influence on the evolution of this market during the forecast period of this study.

The participating companies offer a variety of liquid biopsy diagnostic and monitoring solutions based on a variety of technological approaches, such as the isolation and analysis of ctDNA, CTCs and extracellular vesicles.

“Given the advantages of isolating and analyzing ctDNA compared to CTCs and other analytes, along with the lower barriers to entry in this segment, the ctDNA-based liquid biopsy tests market segment is the most active one, with many competitors engaged in the development and commercialization of such tests,” said Adriana Rusu, biotechnology and IVD market analyst and the report’s author.

The overall market competitiveness increas